Répondant

Veuillez remplir le questionnaire ci-dessous.

Merci !

| Age (years) | _____ |

| Sex | ◯ male |
| | ◯ female |

Job	◯ doctor
	◯ pharmacist
	◯ biologist
	◯ project manager or equivalent
	◯ engineer
	◯ statistician
	◯ other

| Detail | _____ |

| Are you a member of a patient association? | ◯ Oui |
| | ◯ Non |

| Main function | _____ |

Principal place of practice (optional)	◯ Hospital/university
	◯ Inserm
	◯ Health authorities and agencies
	◯ Cooperative group
	◯ CPP
	◯ Pharmaceutical industry
	◯ CRO
	◯ Other

If you have more than one practice location, please specify (optional)	☐ Hospital/university
	☐ Inserm
	☐ Health authorities and agencies
	☐ Cooperative group
	☐ CPP
	☐ Pharmaceutical industry
	☐ CRO
	☐ Other

| Are you personally involved in clinical research? | ◯ Oui |
| | ◯ Non |

| Are you or have you ever been an investigator in a therapeutic trial? | ◯ Oui |
| | ◯ Non |

| Do you have any links of interest with the pharmaceutical industry? | ◯ Oui |
| | ◯ Non |

We would like to know your opinion on innovations in the field of therapeutics.Thank you for answering these questions

Could you give 1 to 3 synonyms for therapeutic innovation?

_____

Could you briefly give 1 or 3 examples in the last 10 years?

_____

Using the example(s) you have chosen, what elements would you suggest are the basis for innovation(s)?

_____

What do you think is the most important factor in spotting an innovation?
- ○ Mechanism of action
- ○ Therapeutic target
- ○ In vitro results
- ○ Animal results
- ○ Method of administration
- ○ Underlying technology

What do you think is the most important factor in confirming an innovation?
- ○ Mechanism of action
- ○ Therapeutic target
- ○ Method of administration
- ○ Underlying technology
- ○ Clinical outcome
- ○ Investment

Please tell us whether you agree with these statements about therapeutic innovations. (0: strongly disagree - 10: strongly agree)

They necessarily propose a new mechanism of action

strongly disagree   strongly agree

(Place a mark on the scale above)

They are based on fundamental research

strongly disagree   strongly agree

(Place a mark on the scale above)

They use new models and currents of thought

strongly disagree   strongly agree

(Place a mark on the scale above)

They use conceptual discoveries

strongly disagree   strongly agree

(Place a mark on the scale above)

They require creativity

strongly disagree   strongly agree

(Place a mark on the scale above)

They will benefit from AI and Big Data

strongly disagree   strongly agree

(Place a mark on the scale above)

They define a new therapeutic family

strongly disagree   strongly agree

(Place a mark on the scale above)

| They may involve a different approach	strongly disagree	strongly agree

(Place a mark on the scale above)

They may concern only one new indication	strongly disagree	strongly agree

(Place a mark on the scale above)

They must bring scientific improvements	strongly disagree	strongly agree

(Place a mark on the scale above)

They must bring clinical improvements	strongly disagree	strongly agree

(Place a mark on the scale above)

They must demonstrate a benefit-risk ratio for patients	strongly disagree	strongly agree

(Place a mark on the scale above)

Please indicate whether you agree with these statements by using innovations ?

especially oncology	strongly disagree	strongly agree

(Place a mark on the scale above)

especially serious diseases	strongly disagree	strongly agree

(Place a mark on the scale above)

especially rare diseases	strongly disagree	strongly agree

(Place a mark on the scale above)

especially paediatrics	strongly disagree	strongly agree

(Place a mark on the scale above)

especially the elderly	strongly disagree	strongly agree

(Place a mark on the scale above)

especially orphan diseases	strongly disagree	strongly agree

(Place a mark on the scale above)

All medical conditions can benefit	strongly disagree	strongly agree

(Place a mark on the scale above)

All diseases can benefit	strongly disagree	strongly agree

(Place a mark on the scale above)

Please tell us whether you agree with these statements about their development (0: strongly disagree - 10: strongly agree).

It is risky

strongly disagree   strongly agree

(Place a mark on the scale above)

It is costly

strongly disagree   strongly agree

(Place a mark on the scale above)

It is too costly

strongly disagree   strongly agree

(Place a mark on the scale above)

It takes a long time

strongly disagree   strongly agree

(Place a mark on the scale above)

It relies on pharmaceutical companies

strongly disagree   strongly agree

(Place a mark on the scale above)

It uses institutional research

strongly disagree   strongly agree

(Place a mark on the scale above)

It is booming

strongly disagree   strongly agree

(Place a mark on the scale above)

What are your main suggestions for improvement?

_____

Before moving on to a clinical evaluation of a therapeutic innovation, can you rank the importance of the data that should be available? Rank from 1 (most important) to 4 (least important).

	1	2	3	4
data on the mechanism of action	○	○	○	○
PK-PD data	○	○	○	○
safety data in animals	○	○	○	○
efficacy data in animals	○	○	○	○

Say whether you agree with these statements about the clinical evaluation of a therapeutic innovation?(0: strongly disagree- 10: strongly agree)

It should follow the same rules as for any treatment

strongly disagree   strongly agree

(Place a mark on the scale above)

It must be simplified

strongly disagree   strongly agree

(Place a mark on the scale above)

Clinical data may not be available	strongly disagree	strongly agree
		☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐
		(Place a mark on the scale above)

Randomised clinical trials may not be available	strongly disagree	strongly agree
		☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐
		(Place a mark on the scale above)

It must give priority to safety data	strongly disagree	strongly agree
		☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐
		(Place a mark on the scale above)

Priority should be given to efficacy data	strongly disagree	strongly agree
		☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐
		(Place a mark on the scale above)

It must give priority to pharmacological data	strongly disagree	strongly agree
		☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐
		(Place a mark on the scale above)

Other comments

Do you see any specific ethical problems with therapeutic innovations?

_____

Do you have any other comments?

_____